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World Hepatitis Day 2016 marks one year since Hepatology, Medicine and Policy (HMAP) began accepting
submissions. There have been many major developments in the fight against hepatitis B virus (HBV) and hepatitis C
virus (HCV) infections during this time, but there is no guarantee that the global community’s interest in these
diseases will endure. Situating efforts to eliminate HBV and HCV within the movement to strengthen health systems
is the key to ensuring that current momentum is sustained. Because of the very nature of viral hepatitis, an effective
response requires the integration of many seemingly disparate components of health systems. Everyone working to
end HBV and HCV epidemics thus has a vested interest in health systems strengthening. Furthermore, it is
important for strategic purposes to look beyond what hepatitis stakeholders need from health systems, and to ask
how the global response to HBV and HCV can help foster health systems innovations and put patient-centered care
first. Addressing this question explicitly is central to ensuring that the long-term relevance of the viral hepatitis
movement is recognized by diverse health and development actors.Editorial
Hepatology, Medicine and Policy (HMAP) came into
being one year ago, on World Hepatitis Day 2015. Our
call for submissions generated widespread interest, and
we began publishing during the International Liver Con-
gress (ILC) in April 2016. We are deeply indebted to the
many experts who joined the editorial board of our
fledgling journal, to the associate editors who oversee ar-
ticles, to the authors who dared to submit to a new jour-
nal and to the staff at our publisher.
The past year has been eventful. The first World Hepa-
titis Summit brought together patients, healthcare profes-
sionals, government leaders, World Health Organization
(WHO) officials and other stakeholders for three days of
learning and strategizing in September 2015 [1]. The real-
world efficacy and safety of powerful new direct-acting
antiviral (DAA) treatments for hepatitis C virus (HCV)
infection was confirmed in research presented at the ILC
in April 2016 [2, 3]. WHO’s first-ever global health sector
strategy on viral hepatitis was adopted in May 2016 [4].* Correspondence: Jeffrey.Lazarus@regionh.dk
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introduced the “NOhep” campaign to end viral hepatitis
[5], and the full elimination of one or more viral hepatiti-
des is increasingly recognised as an attainable goal.
But what are we to make of the outpouring of interest
in viral hepatitis and the much-increased visibility of this
group of diseases? Is the world finally awakening to the
magnitude of the problem? Or is this just a transitory
phenomenon?
We raise the question because the medical and public
health fields, in spite of aspiring to be the embodiment
of rationality, are remarkably trend-driven in some
regards. It is not unheard of for a disease or health issue
to have its moment in the sun, suddenly enjoying an
upsurge of interest among researchers, donors, govern-
ment officials and the general public, then for the inter-
est to dissipate. Just look at the current Zika virus
epidemic, the 2014–2015 Ebola hemorrhagic fever out-
break, and influenza pandemics before that.
Many people in our circles have suggested that the
years 2015 and 2016 mark a turning point in the global
fight against HBV and HCV. Five years on, will we in-
deed look back at this as the time when a movement
coalesced, and the stage was set for us to drive force-
fully toward elimination of these two diseases? Or will
it be remembered as a period when viral hepatitis brieflyle is distributed under the terms of the Creative Commons Attribution 4.0
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was quickly forgotten?
When we think about how to capitalize on current
opportunities, and how to ensure that momentum is
sustained, we are struck by the importance of situating
efforts to end HBV and HCV epidemics within the
movement to strengthen health systems. The concept of
“health systems strengthening” may seem like an ab-
straction to biomedical, technical and health service
experts who are accustomed to thinking in terms of liver
fibrosis stages, seroprevalence data and quantities of
clean needles and syringes distributed to people who in-
ject drugs. But we urge people to step back from their
diverse areas of hepatitis-related expertise and take stock
of how this work fits into health systems strengthening.
In making this proposal, we are thinking specifically of
the conceptualization of health systems strengthening as
“permanently making the system function better, not just
filling gaps or supporting the system to produce better
short-term outcomes” [6]. The latter approach is often
motivated by health crises, for example a dramatic in-
crease in the prevalence of a particular disease or a surge
in demand for health services in the wake of a natural
disaster. All too often it results in governments and
international partners working in fragmented, episodic
and inefficient ways to address individual public health
challenges rather than building up the capacity of the
health system to address a large constellation of current
and future challenges in an integrated manner.
The Ebola epidemic dramatically exposed longstanding
health system weaknesses in Guinea, Liberia and Sierra
Leone, including financial, human resource and service
delivery weaknesses [7, 8]. What many people may not
realize is that less headline-friendly health system fail-
ures are occurring in countries at all income levels on
an ongoing basis. These failures take myriad forms.
Consider, for example, that almost one-quarter of HIV-
positive people in the United Kingdom do not know
their HIV status [9], and that more than half of the esti-
mated 11 million undocumented immigrants residing in
the United States lack any form of health insurance [10].
So what does the drive to eliminate HBV and HCV
infections have to do with health systems strengthening?
Well, everything. Because of the very nature of these dis-
eases, an effective response requires the integration of
many seemingly disparate components of health systems.
In other words, those of us working to end HBV and
HCV epidemics vitally need health systems strengthening
efforts to be successful if we are to achieve our goals.
Furthermore, it is important for strategic purposes to
look beyond what we need from health systems. How
can the global response to viral hepatitis help to foster
health systems innovations and put patient-centered care
first? Addressing this question explicitly is the key toensuring that the long-term relevance of the fight
against viral hepatitis is recognized by diverse health and
development actors.
Barriers to achieving full hepatitis B vaccine coverage
among infants in some countries, for example, need to
be considered from the standpoint of how well national
health systems are addressing infant and childhood vac-
cination overall. Another issue that cannot be addressed
successfully in isolation is viral hepatitis prevention among
people who inject drugs. Meeting the health-related needs
of this population requires cross-disciplinary collaboration
among experts on multiple health issues, including addic-
tion, other mental health issues, and various infectious and
noncommunicable diseases. How might a health system’s
full array of resources, including service delivery, financing
and health information systems, be best configured to
optimize health outcomes in light of these considerations?
Those of us working primarily on viral hepatitis-related
issues do not have any easy answers—but we have a
responsibility to explore how health system-related factors
might enhance or undermine the effectiveness of the in-
terventions that we wish to see brought to scale. We also
can articulate the challenges of our work to the larger
health systems community in ways that encourage benefi-
cial changes. We might, for example, choose to press the
question of whether the widespread convention of dichot-
omizing diseases as either infectious or noncommunicable
has outlived its usefulness. Hepatitis B and hepatitis C are
infectious diseases that give rise to liver cancer, cirrhosis
and liver failure. In some settings, coinfection with
multiple hepatitis viruses, as well as with HIV and other
infectious agents, is not uncommon. Effective disease sur-
veillance systems need to integrate data that are reflective
of all of these considerations.
So this World Hepatitis Day, as we set our sights on
the WHO goal of eliminating HBV and HCV as a major
public health threat by 2030 [11], let’s think about how
the response to viral hepatitis can become more holistic
and how it can be contextualized for every health sys-
tem, large and small, from the national to the local level.
Enacting this vision will extend the benefits of our ac-
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